Articles tagged "Immunosuppression"

2017 American Transplant Congress
Utility of Weighted Composite Endpoints in Kidney Transplantation.
J. Schold, D. Goldfarb, S. Flechner, L. Buccini, J. Augustine, E. Poggio.
Cleveland Clinic, Cleveland, OH
IntroductionAdvances in therapeutic development and innovation are stifled in transplantation based on difficulties demonstrating efficacy of novel interventions using standard endpoints. Current RCTs are constrained…
2017 American Transplant Congress
Avoidance or Reduction of Rituximab Might Improve Clinical Outcomes in ABO-Incompatible Renal Transplantation: Advantages and Disadvantages of Rituximab.
M. Okada,¹ Y. Watarai,¹ K. Iwasaki,² K. Murotani,³ T. Hiramitsu,¹ M. Tsujita,¹ N. Goto,¹ S. Narumi,¹ T. Kobayashi.²
¹Transplant and Endocrine Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan; ²Renal Transplant Surgery, Aichi Medical University, Nagakute, Japan; ³Clinical Research Center, Aichi Medical University, Nagakute, Japan
BACKGROUNDPretransplant desensitization with rituximab has contributed to drastic improvements in ABO-incompatible renal transplantation (ABO-I). However, ABO-I outcomes are still worse than those of ABO-identical or…
2017 American Transplant Congress
Risk Factors for Polyomavirus Infection After Renal Transplantation: Introduction of the Protective Effect of Peritoneal Dialysis.
S. Hosseini-Moghaddam, Q. Xu, J. Kum, H. Alharbi, A. Jevnikar, M. John, G. Singh, S. Parsons, M. Edgar, P. Luke.
Medicine, Western University, London Health Sciences Centre, London, ON, Canada
Objective: To determine the roles of pre and post-transplant variables on the risk of BK virus infection after renal transplantation.Method: This study is a single-…
2017 American Transplant Congress
The Adoption of Generic Immunosuppressant Medications Among Kidney and Liver Transplant Recipients Using the Colorado All Payer Claims Database.
Q. Liu,¹ A. Smith,¹ J. Park,² M. Oguntimein,³ S. Dutcher,³ G. Bello,¹ M. Helmuth,¹ M. Turenne,¹ R. Balkrishnan,⁴ M. Fava,¹ P. Sharma,² C. Beil,¹ A. Leichtman,¹ J. Zee.¹
¹Arbor Research Collaborative for Health, Ann Arbor, MI; ²U of Michigan, Ann Arbor, MI; ³Food and Drug Administration, Silver Spring, MD; ⁴U of Virginia, Charlottesville, VA
Background: Substitution of generic for brand-name immunosuppressants has increased in solid organ transplantation following the expiration of brand patents. Our aim was to describe the…
2017 American Transplant Congress
The Effect of Low-Dose IL-2 in Clinical Facial Transplantation: Molecular and Immunological Response.
N. Murakami,¹ T. Win,¹ T. Borges,¹ C. Lian,¹ G. Murphy,¹ E. Bueno,¹ R. Clark,¹ T. Strom,² B. Pomahac,¹ L. Riella.¹
¹Brigham and Women's Hospital, Boston; ²Beth Israel Deaconess Medical Center, Boston
BackgroundRegulatory T cells (Tregs) play a critical role in immune tolerance and low-dose recombinant IL-2 administration has been reported to expand Tregs in vivo. Although…
2017 American Transplant Congress
Is There a Role for Electronic Health Service in of Therapeutic Drug Monitoring of Immunosuppression?
M. Barten,¹ I. Hausladen,² F. Mohr, J. Garbade.
¹Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; ²Cardiac Surgery, University Hospital Leipzig, Heart Center, Leipzig, Germany
Background: Therapeutic drug monitoring (TDM) of immunosuppression is critical to avoid rejection or toxic side effects by under- or over-immunosuppression after heart transplantation (HTx). Hence,…
2017 American Transplant Congress
Conversion from Twice Daily to Once Daily Tacrolimus Improves Adherence in Kidney Transplant Recipients.
M. Levine,¹ K. Wen.²
¹Division of Urology, University of Alberta, Edmonton, AB, Canada; ²Department of Nephrology, University of Alberta, Edmonton, AB, Canada
INTRODUCITON AND OBJECTIVE: Kidney transplant longevity is largely related to immunosuppressive efficacy, which is highly dependent on patient adherence. Drug dosing frequency is one way…
2017 American Transplant Congress
Anti-CD25mAb Sparing Immunosuppressive Regimen Suppressed Recurrence of Post-Transplant Focal Segmental Glomerular Sclerosis- A Single Center Experience.
H. Harada, Y. Wada, N. Fukuzawa.
Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Japan
INTRODUCTION: The rate of recurrence of primary focal segmental glomerular sclerosis (FSGS) is problematic, because it often results in very early serious urinary protein secretion…
2017 American Transplant Congress
Lipid Abnormalities and Cardiovascular Events After Early Conversion to Everolimus in Kidney Transplant Recipients with Pretransplant Diabetes: 24-Month Analysis from Elevate Study.
M. van der Giet,¹ J. de Fijter,¹ F. Oppenheimer,¹ G. Russ,¹ P. Lopez,² G. Bader,² J. Cruzado,¹ H. Holdaas.¹
¹ELEVATE Study Group, Berlin, Germany; ²Novartis Pharma AG, Basel, Switzerland
PURPOSE: Pretransplant (preTx) diabetes is an independent risk factor for cardiovascular (CV) events, and posttransplant (post-Tx) hyperlipidemia further increases CV risk. To analyze the influence…
2017 American Transplant Congress
Steroid-Free Immunosuppression After Liver Transplant for Autoimmune Disease Does Not Result in Increased Disease Recurrence.
A. Hooper,¹ C. Frenette.²
¹Internal Medicine, Scripps Mercy Hospital, San Diego, CA; ²Organ Transplant, Scripps Green Hospital, La Jolla, CA
Immunosuppression regimens in patients with end stage liver disease (ESLD) from autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) typically include…